1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond

por Joshi, K., Muhith, A., Milner-Watts, C., Obeid, M., Khakoo, S., Bhosle, J., Minchom, A.R., O'Brien, M.
Publicado en Ann Oncol (2020)

1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience

por Cui, W., Yousaf, N., Bhosle, J., Minchom, A.R., Ahmed, M., McDonald, F., Locke, I., Lee, R., O'Brien, M., Popat, S.
Publicado en Ann Oncol (2020)

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

por Cui, W., Milner-Watts, C., Saith, S., Bhosle, J., Minchom, A.R., Davidson, M., Page, S., Locke, I., Yousaf, N., Popat, S., O'Brien, M.E.R.
Publicado en J Thorac Oncol (2021)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine bl...

por Minchom, A R, Saksornchai, K, Bhosle, J, Gunapala, R, Puglisi, M, Lu, S K, Nimako, K, Coward, J, Yu, K C, Bordi, P, Popat, S, O'Brien, M E R
Publicado en BMJ Open Respir Res (2014)